Table of Contents
Cell and gene therapies can cost over $4 million per dose.
Yet many programmes stall before reaching patients, with manufacturing complexity a leading cause.
The global cell and gene therapy CDMO market is on track to roughly triple by 2031, making the right manufacturing partner increasingly the difference between approval and a therapy that never reaches patients.
adthera bio, the UK-based digital-first CDMO that broke cover in May 2023 with backing from Delin Ventures, is taking aim at that bottleneck.
The team brings over 100 years of combined ATMP experience from GSK, Novartis, Sanofi and Miltenyi Biotec.
Their facilities span purpose-built process development and analytical labs alongside a separate GMP production unit across Birmingham and London.
At Advanced Therapies 2026, Onyx sat down with Chief Development & Manufacturing Officer, Stuart Curbishley, to find out more.
A special thanks to our Onyx Live sponsors:
HUMPHREYS LAW – a focused, full-service law firm advising clients in the technology and media sectors. https://humphreys.law/
Panacea – AI-powered FDA consultants. File your IND in half the time. https://withpanacea.com/
Coming up: Cell & Gene Leaders Live, Sun 15 Nov at The Shard · London Life Sciences Week Guide, 15–19 Nov 2026 ·
Comments